Werkgroep Cardiologische centra Nederland English

CANTOS (Follow up)

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Middel
canakinumab
Populatie
acuut coronair syndroom
Fase
fase III
Jaar aanvang
2011
Meer informatie
ClinicalTrials.gov